Capricor Therapeutics (CAPR) Change in Interest Receivables (2013 - 2014)
Capricor Therapeutics' (CAPR) quarterly Change in Interest Receivables came in at $593.0 in Q3 2014, up 105.25% year-on-year from $288.91 in Q3 2013, and up 212.52% quarter-over-quarter from -$527.0 in Q2 2014.
Capricor Therapeutics (CAPR) Change in Interest Receivables (2013 - 2014) Analysis & Trends
Capricor Therapeutics' Change in Interest Receivables history runs 2 years deep, the most recent figure standing at $593.0 for Q3 2014.
- On a quarterly basis, Change in Interest Receivables rose 105.25% year-over-year to $593.0 in Q3 2014; TTM through Sep 2014 was -$2604.0, a N/A change from a year earlier, with the FY2013 full-year figure at -$25028.0, down 199.26% from the prior year.
- Change in Interest Receivables advanced to $593.0 in Q3 2014 per CAPR's latest filing, from -$527.0 in the prior quarter.
- Across five years, Change in Interest Receivables topped out at $593.0 in Q3 2014 and bottomed at -$11292.0 in Q3 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -266,893.98 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Capricor Therapeutics | 1.12 Bn | 1.12 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | 593.00 |
| Jun 30, 2014 | -527.00 |
| Mar 31, 2014 | 570.00 |
| Dec 31, 2013 | -3,240.00 |
| Sep 30, 2013 | -11,292.00 |
| Jun 30, 2013 | -2,222.00 |
| Mar 31, 2013 | -8,274.00 |